[HTML][HTML] Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
M Stelmachowska-Banaś, I Czajka-Oraniec, A Tomasik… - Pituitary, 2022 - Springer
Context Pasireotide-LAR, a second-generation somatostatin receptor ligand (SRL), is
recommended for patients with acromegaly as second-line treatment. Its efficacy and safety …
recommended for patients with acromegaly as second-line treatment. Its efficacy and safety …
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of …
G Corica, R Pirchio, A Milioto, F Nista, A Arecco… - Journal of …, 2024 - Springer
Purpose To evaluate the impact of pasireotide (PAS) therapy on hormonal and
glycometabolic outcome in patients with acromegaly previously treated with combination …
glycometabolic outcome in patients with acromegaly previously treated with combination …
[HTML][HTML] Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective
F Nista, G Corica, L Castelletti, K Khorrami… - Frontiers in …, 2021 - frontiersin.org
Background First-generation somatostatin receptor ligands (fg-SRLs) represent the first-line
medical treatment for acromegaly, recommended in patients with persistent disease after …
medical treatment for acromegaly, recommended in patients with persistent disease after …
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study
C Campana, PM van Koetsveld… - European Journal of …, 2022 - academic.oup.com
Objective The aim of this study was to develop an open-source and reproducible digital
quantitative analysis (DIA) of somatostatin receptor subtype 2a (SST2) staining in formalin …
quantitative analysis (DIA) of somatostatin receptor subtype 2a (SST2) staining in formalin …
[HTML][HTML] gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
LE Wildemberg, D Henriques, PCL Elias, CHA Lima… - Cancers, 2021 - mdpi.com
Simple Summary Acromegaly treatment consists of surgical, medical, and radiation therapy.
First-generation somatostatin receptor ligands are the mainstay of medical therapy, with …
First-generation somatostatin receptor ligands are the mainstay of medical therapy, with …
Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas
Purpose Patterns of extension of pituitary adenomas (PA) may vary according to PA subtype.
Understanding extrasellar extension patterns in growth hormone PAs (GHPA) vis-a-vis …
Understanding extrasellar extension patterns in growth hormone PAs (GHPA) vis-a-vis …
Emerging drugs for the treatment of acromegaly
C Campana, G Corica, F Nista… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Acromegaly is a disease characterized by elevated growth hormone (GH) and
insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while …
insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while …
[HTML][HTML] Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects
J Amarù, F Barbieri, M Arvigo, A Solari, A Bajetto… - Cancers, 2021 - mdpi.com
Simple Summary First-generation somatostatin receptor ligands, such as octreotide, are the
first-line medical therapy in acromegaly. Octreotide shows preferential binding for …
first-line medical therapy in acromegaly. Octreotide shows preferential binding for …
A brief atlas of insulin
E Ayan, H DeMirci - Current Diabetes Reviews, 2023 - ingentaconnect.com
Insulin is an essential factor for mammalian organisms: a regulator of glucose metabolism
and other key signaling pathways. Insulin is also a multifunctional hormone whose absence …
and other key signaling pathways. Insulin is also a multifunctional hormone whose absence …
[HTML][HTML] Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma
DW Tucker, DJ Pangal, R Du, AS Gogia, A Tafreshi… - Plos one, 2023 - journals.plos.org
Introduction Many patients with growth hormone-secreting pituitary adenoma (GHPA) fail to
achieve biochemical remission, warranting investigation into epigenetic and molecular …
achieve biochemical remission, warranting investigation into epigenetic and molecular …